ESSA Pharma Inc. (EPIX) |
| 0.2012 -0.004 (-1.85%) 10-13 16:00 |
| Open: | 0.2012 |
| High: | 0.2012 |
| Low: | 0.2012 |
| Volume: | 5,945,141 |
| Market Cap: | 10(M) |
| PE Ratio: | -0.35 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 32.74 |
| Resistance 1: | 32.12 |
| Pivot price: | 32.08 |
| Support 1: | 31.13 |
| Support 2: | 25.90 |
| 52w High: | 6.45 |
| 52w Low: | 0.18 |
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Thu, 09 Oct 2025
Up to $6.7M CVR: ESSA Acquired by XenoTherapeutics for $0.1242/Share; Nasdaq delisting expected - Stock Titan
Thu, 09 Oct 2025
XenoTherapeutics completes acquisition of ESSA Pharma - Investing.com
Tue, 07 Oct 2025
ESSA Pharma (EPIX) Shareholders Approve Acquisition by XenoThera - GuruFocus
Mon, 06 Oct 2025
ESSA securityholders approve acquisition by XenoTherapeutics - Investing.com
Wed, 24 Sep 2025
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics - Yahoo Finance
Wed, 24 Sep 2025
ESSA Pharma amends agreement with XenoTherapeutics, lowers payout - Investing.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
